Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | See Remarks | September 16, 2026 | September 18, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, General Counsel | September 04, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,508 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 3,674 · Balance 112,508 F1: The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
HALOZYME THERAPEUTICS, INC.
Report date September 04, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,049 |
Ending reported balance
After 2021-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-09-04 · Exercise / conversion · Acquired 6,883 · Balance 23,461 Row 2 · 2021-09-04 · Tax withholding · Disposed 3,412 · Balance 20,049 F1: The reported disposition of 3,412 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,883 |
Reported balance
After 2021-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-04 · Exercise / conversion · Disposed 6,883 · Balance 6,883 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 3,412 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2023 Filed Jun 3, 2023 00:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000066 · wk-form4_1685752267.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,976 F1 · shares: Represents Performance Stock Units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 55,800 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001567619-23-004542 · doc1.xml · derivative · entry 4 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,800 Underlying: Common Stock · 55,800 shares Expires 2033-03-02 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004542 · doc1.xml · nonDerivative · entry 3 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,101 F3 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 18 | $16.52 | $297.36 |
DisclosureSEC source: 0001567619-23-004542 · doc1.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,101 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,416 | $15.82 | $22,398.43 |
DisclosureSEC source: 0001567619-23-004542 · doc1.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,119 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,720 | $18.19 | $31,288.86 |
DisclosureSEC source: 0001787306-22-000077 · wf-form4_166916195632010.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,535 F3 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 13,300 Restricted Stock Units ("RSUs"). Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-22-000077 · wf-form4_166916195632010.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,255 F1 · shares: Represents performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on November 18, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. F2 · balance_after: Includes 13,300 Restricted Stock Units ("RSUs"). Read SEC document |
| June 02, 2022 Filed Jun 2, 2022 20:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,795 | $19.73 | $35,418.58 |
DisclosureSEC source: 0001567619-22-012149 · doc1.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,380 F3 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable withholding taxes. F4 · price: The transaction was executed in multiple trades in prices ranging from $19.7201 to $19.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 13,300 RSUs. Read SEC document |
| May 27, 2022 Filed Jun 2, 2022 20:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012149 · doc1.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,175 F1 · shares: Represents performance stock units ("PSUs") initially granted on January 3, 2022 that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. F2 · balance_after: Includes 13,300 RSUs. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006496 · doc1.xml · derivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006496 · doc1.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 13,300 RSUs. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $22.79 | $0.00 |
DisclosureSEC source: 0001567619-22-000671 · doc1.xml · derivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary measured from January 3, 2022 (the "Vesting Commencement Date"), and 1/48th of the shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 04, 2021 Filed Sep 7, 2021 21:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,883 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008662 · edgar.xml · derivative · entry 3 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,883 Underlying: Common Stock · 6,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| September 04, 2021 Filed Sep 7, 2021 21:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,412 | $42.22 | $144,054.64 |
DisclosureSEC source: 0001179110-21-008662 · edgar.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,049 F1 · shares: The reported disposition of 3,412 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| September 04, 2021 Filed Sep 7, 2021 21:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008662 · edgar.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 22:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 13,544 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001811 · edgar.xml · derivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,544 Underlying: Common Stock · 13,544 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 22:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 23,311 | $0.00 Strike: $49.84 | $0.00 |
DisclosureSEC source: 0001179110-21-001811 · edgar.xml · derivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,311 Underlying: Common Stock · 23,311 shares Expires 2031-02-15 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock · Derivative | 4,129 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001653 · edgar.xml · derivative · entry 6 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,258 Underlying: Common Stock · 4,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,047 | $49.84 | $102,022.48 |
DisclosureSEC source: 0001179110-21-001653 · edgar.xml · nonDerivative · entry 4 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F2 · shares: The reported disposition of 2,047 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001653 · edgar.xml · nonDerivative · entry 3 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,257 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001653 · edgar.xml · derivative · entry 5 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,769 Underlying: Common Stock · 6,257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,203 | $50.60 | $162,071.80 |
DisclosureSEC source: 0001179110-21-001653 · edgar.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,496 F1 · shares: The reported disposition of 3,203 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001653 · edgar.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2020 Filed Sep 4, 2020 22:13 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,884 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009605 · edgar.xml · derivative · entry 3 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,766 Underlying: Common Stock · 6,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| September 04, 2020 Filed Sep 4, 2020 22:13 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,380 | $27.70 | $65,926.00 |
DisclosureSEC source: 0001179110-20-009605 · edgar.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,442 F1 · shares: The reported disposition of 2,380 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| September 04, 2020 Filed Sep 4, 2020 22:13 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009605 · edgar.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001583 · edgar.xml · derivative · entry 3 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,387 Underlying: Common Stock · 4,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,681 | $20.00 | $33,620.00 |
DisclosureSEC source: 0001179110-20-001583 · edgar.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,938 F1 · shares: The reported disposition of 1,681 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001583 · edgar.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 25,026 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001536 · edgar.xml · derivative · entry 2 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,026 Underlying: Common Stock · 25,026 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 53,211 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001179110-20-001536 · edgar.xml · derivative · entry 1 Matsuda Masaru · CIK 0001798679 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,211 Underlying: Common Stock · 53,211 shares Expires 2030-02-10 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.